Group 1: ETF Performance - The liquidity of the Kexin Pharmaceutical ETF managed by Jiashi showed a turnover rate of 10.3% with a transaction volume of 21.45 million yuan, indicating active market trading [3] - Over the past week, the average daily transaction volume reached 39.89 million yuan, ranking first among comparable funds [3] - In terms of scale, the Kexin Pharmaceutical ETF saw an increase of 3.11 million yuan in the past month, also ranking first among comparable funds [3] - The fund's net asset value increased by 42.32% over the past year, placing it in the top 18.42% among 2,931 index equity funds [3] Group 2: Top Holdings - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index accounted for 50.3% of the index [3] - The top stocks include: - United Imaging Healthcare (9.73%) - BeiGene (6.04%) - Huatai Medical (5.69%) - Baillie Gifford (5.35%) - Ailis (4.76%) - Zai Lab (4.53%) - Junshi Biosciences (4.15%) - Borui Pharmaceutical (3.60%) - BGI Genomics (3.07%) - Yifang Biotechnology (3.03%) [5] Group 3: Market Outlook - CITIC Construction Investment Securities remains optimistic about innovative drugs and high-barrier generic drugs, highlighting the National Medical Insurance Administration's ongoing efforts in centralized procurement and negotiation [6] - Southwest Securities emphasizes the acceleration of value reconstruction in innovative drugs and their industrial chain, driven by overseas business development, research and commercialization progress, and policy support [6]

Core Points - The current season marks the implementation of dividend distribution for listed companies, with 24 companies executing their distribution plans today [1] - A total of 3,679 companies have announced distribution plans for the 2024 fiscal year, with 3,674 of them including cash dividends, amounting to a total cash payout of 1.64 trillion yuan [1] - The distribution plans also include stock transfers, with 346 companies offering such options [1] Group 1 - The key dates for investors focusing on dividends are the ex-dividend date and the record date, with 3,421 companies having already implemented their distribution plans [1] - Investors interested in dividends may consider "抢权" (rights grabbing) before the record date, which is the last trading day to qualify for the current dividend [1] - Among the 24 companies with a record date today, 16 companies are offering cash dividends of 1 yuan (after tax) or more per 10 shares, with 博隆技术 offering the highest at 7.50 yuan per 10 shares [1][2] Group 2 - The highest stock transfer ratio among the companies with a record date today is also from 博隆技术, which has a distribution plan of 10 shares for every 2 shares transferred, along with a cash dividend of 7.5 yuan [2] - In terms of stock performance, 国机通用 has seen the highest increase over the past five days, with a cumulative rise of 21.42%, followed by 梓橦宫 and 氯碱化工 [2] - A detailed list of companies implementing dividend distributions includes their respective cash payouts, stock transfer ratios, latest closing prices, and five-day price changes [2][3]

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

本次利润分配方案经公司2025 年 6 月 12 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 证券代码：688710 证券简称：益诺思 公告编号：2025-023 上海益诺思生物技术股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/22 | 2025/7/23 | 2025/7/23 | 一、 通过分配方案的股东大会届次和日期 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本140,979,615股为基数，每股派发现 金红利0.32元（含税），共计派发现金红利45,113,476.80元。 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0 ...

证券代码：688710 证券简称：益诺思 公告编号：2025-022 上海益诺思生物技术股份有限公司 关于控股子公司拟进行业务调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 控股子公司业务调整概述 为进一步优化上海益诺思生物技术股份有限公司（以下简称"公司""上海 益诺思"）产能配置，降低管理成本，提高管理效率和管控能力，结合公司控股 子公司深圳市益诺思生物医药安全评价研究院有限公司（以下简称"深圳益诺 思"）实际经营情况，深圳益诺思将进行业务调整，除存续业务以外不再承接新 业务；同时公司募集资金投资项目（以下简称"募投项目"）已按计划顺利推进， 全资子公司益诺思生物技术南通有限公司（以下简称"南通益诺思"）所实施的 募投项目"高品质非临床创新药物综合评价平台扩建项目"将逐步投入使用，后 续新增业务将由上海益诺思及南通益诺思承接。 二、 控股子公司基本情况 （一）基本情况 1、公司名称：深圳市益诺思生物医药安全评价研究院有限公司 2、成立时间：2021 年 11 月 9 日 3、注册资本：2,000 万元 ...

Core Viewpoint - The company is optimizing its capacity allocation and management efficiency by adjusting the business operations of its subsidiary, Shenzhen Yinos Bio-pharmaceutical Safety Evaluation Research Institute Co., Ltd, which will no longer undertake new business except for existing operations [1] Financial Summary - Shenzhen Yinos was established in November 2021 with a registered capital of 20 million yuan [1] - As of 2024, the total assets of the company were 115 million yuan, with a net asset value of -64.87 million yuan, operating revenue of 65.71 million yuan, and a net profit of -21.50 million yuan [1] - By March 31, 2025, the total assets decreased to 105 million yuan, net assets further declined to -71.61 million yuan, operating revenue dropped to 14.92 million yuan, and net profit improved slightly to -6.73 million yuan [1]

证券代码：688710 证券简称：益诺思 公告编号：2025-021 上海益诺思生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 12 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区郭守敬路 199 号中 心报告厅 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 64 | | --- | --- | | 普通股股东人数 | 64 | | 2、出席会议的股东所持有的表决权数量 | 96,448,952 | | 普通股股东所持有表决权数量 | 96,448,952 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 68.4134 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 68.4134 | （ ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN HONG KONG PARIS MADRID SILICON VALLEY 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于上海益诺思生物技术股份有限公司 2024 年年度股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 ...

证券代码：688710 证券简称：益诺思 上海益诺思生物技术股份有限公司 2024 年年度股东大会会议资料 上海益诺思生物技术股份有限公司 2024 年年度股东大会 会议资料 二〇二五年六月 | 2024年年度股东大会须知 3 | | | --- | --- | | 2024年年度股东大会会议议程 | 5 | | 议案一：关于公司《2024年度董事会工作报告》的议案 6 | | | 议案二：关于公司《2024年度监事会工作报告》的议案 14 | | | 议案三：关于公司《2024年度财务决算报告》的议案 19 | | | 议案四：关于公司《2025年度财务预算报告》的议案 24 | | | 议案五：关于公司《2024年年度报告》及摘要的议案 26 | | | 议案六：公司2024年度利润分配方案 | 27 | | 听取事项：公司独立董事2024年度述职报告 | 28 | 2024年年度股东大会须知 根据中国证券监督管理委员会相关规则和《公司章程》的有关规定，为确 保公司股东大会顺利召开，特制定大会须知如下，望出席股东大会的全体人员 遵守执行： 一、公司董事会办公室具体负责大会有关程序、资料相关的事宜。 二、股 ...

北京 上海 深圳 杭州 广州 昆明 天津 成都 宁波 福州 西安 南京 南宁 济南 香港 巴黎 马德里 硅谷 BEIJING SHANGHAI SHENZHEN HANGZHOU GUANGZHOU KUNMING TIANJIN CHENGDU NINGBO FUZHOU XI'AN NANJING NANNING JINAN HONG KONG PARIS MADRID SILICON VALLEY 上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于上海益诺思生物技术股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：上海益诺思生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《 ...